Skip to content
  • Tuesday, 27 October 2026
  • 4:29 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • European Commission Approves Expanded Use of Crysvita (burosumab) for Infants with X-Linked Hypophosphatemia
Pharmaceutical R&D

European Commission Approves Expanded Use of Crysvita (burosumab) for Infants with X-Linked Hypophosphatemia

Teuku Ryan Jul 23, 2026 0

Kyowa Kirin EMEA, a subsidiary of Kyowa Kirin, has secured a significant approval from the European Commission (EC) to broaden…

Read More
Pharmaceutical R&D

Kyowa Kirin Secures FDA Approval for Enhanced Crysvita Dosing Regimen for Adults with X-Linked Hypophosphatemia

Teuku Ryan May 16, 2026 0

Kyowa Kirin has announced a significant advancement in the treatment landscape for X-linked hypophosphatemia (XLH) in adult patients, following the…

Read More
Finnish Researchers Achieve Unprecedented Sensitivity in Quantum Energy Detection Breaking the Zeptojoule BarrierINTEGRA Biosciences Automates Quantabio sparQ DNA Frag & Library Prep Kit Workflow, Enhancing NGS Efficiency and ReproducibilityBeyond the Statistics: Analyzing the True State of Laboratory Safety in the Modern EraAdvancing Gene Expression Analysis: Droplet Digital PCR Revolutionizes Precision and Sensitivity in Biomedical Research
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ